



Lori Shilbinette
Commissioner

Patricia M. Tilley
Director

STATE OF NEW HAMPSHIRE
DEPARTMENT OF HEALTH AND HUMAN SERVICES

DIVISION OF PUBLIC HEALTH SERVICES
29 HAZEN DRIVE, CONCORD, NH 03301
603-271-4501 1-800-852-3345 Ext. 4501
Fax: 603-271-4827 TDD Access: 1-800-735-2964 www.dhhs.nh.gov

31
MAN

November 22, 2021

The Honorable Karen Umberger, Chairman
Fiscal Committee of the General Court and

His Excellency, Governor Christopher T. Sununu
and the Honorable Council
State House
Concord, New Hampshire 03301

REQUESTED ACTION

1. Pursuant to the provisions of RSA 14:30-a, VI, authorize the Department of Health and Human Services, Division of Public Health Services, to accept and expend federal funds in the amount of \$1,316,765 from the Centers for Disease Control and Prevention (CDC) to fund the Immunization Program under the Consolidated Appropriations Act, 2021 (P.L. 116-260), which contained the Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (P.L. 116-260, Section 2, Division M, Title III) effective upon approval by the Fiscal Committee and Governor and Council through June 30, 2023, and further authorize the funds to be allocated as follows. 100% Federal Funds.
2. Contingent upon the approval of Requested Action #1, pursuant to RSA 124:15, authorize the Department of Health and Human Services, Division of Public Health Services to continue three temporary full-time positions for immunization purposes effective upon approval by the Fiscal Committee and Governor and Council through June 30, 2023. 100% Federal Funds.

05-95-90-902510-5178-HEALTH AND SOCIAL SERVICES, DEPT OF HEALTH AND HUMAN SERVICES; HHS: DIVISION OF PUBLIC HEALTH, BUREAU OF INFECTIOUS DISEASE CONTROL, IMMUNIZATION PROGRAM

SFY2022 Class/Object	Class Title	Current Authorized Budget	This Request	Adjusted Budget
Revenue				
000-404706	Federal Funds	\$ 3,466,910	\$ 1,316,765	\$ 4,783,675
	General Funds	\$ 659,980	\$ -	\$ 659,980
Total Revenue:		\$ 4,126,890	\$ 1,316,765	\$ 5,443,655
Expense				
010-500100	Personal Services Perm	\$ 895,295	\$ -	\$ 895,295
018-500106	Overtime	\$ 2,000	\$ 30,304	\$ 32,304
020-500200	Curent Expenses	\$ 33,431	\$ -	\$ 33,431
026-500251	Organizational Dues	\$ 3,500	\$ -	\$ 3,500
030-500311	Equipment-New Replacement	\$ 1,000	\$ 5,396	\$ 6,396
037-500173	Technology-Hardware	\$ 6,600	\$ -	\$ 6,600
038-500175	Technology-Software	\$ 9,196	\$ 17,114	\$ 26,310
039-500188	Telecommunications	\$ 2,200	\$ -	\$ 2,200
041-500801	Audit Fund Set Aside	\$ 2,117	\$ 1,893	\$ 4,010
042-500620	Post Retirements Benefits	\$ 79,144	\$ -	\$ 79,144
046-500464	Consultants	\$ 100	\$ -	\$ 100
050-500109	Personal Service - Temp	\$ 40,865	\$ 12,520	\$ 53,385
059-500117	Temp Full Time	\$ 91,826	\$ 283,231	\$ 375,057
060-500601	Benefits	\$ 585,230	\$ 188,906	\$ 774,136
066-500544	Employee Training	\$ 500	\$ -	\$ 500
070-500704	In State Travel Reimb	\$ 12,000	\$ 1,150	\$ 13,150
074-500589	Grants for Pub Asst and Rel	\$ 307,827	\$ -	\$ 307,827
080-500714	Out of State Travel Reimb	\$ 8,500	\$ -	\$ 8,500
102-500731	Contracts for Program Services	\$ 1,481,660	\$ 776,251	\$ 2,257,911
103-502507	Contracts for Op Services	\$ 354,503	\$ -	\$ 354,503
513-500355	Vaccine Purchases	\$ 155,850	\$ -	\$ 155,850
548-500396	Reagents	\$ 53,545	\$ -	\$ 53,545
Total Expense:		\$ 4,126,890	\$ 1,316,765	\$ 5,443,655

EXPLANATION

This request is being made to budget previously accepted unspent COVID-19 grant funds for SFY 2022 to administer and support programmatic needs to focus on the work of implementing and expanding New Hampshire's COVID-19 vaccination program under the Coronavirus Response and Relief Supplemental Appropriations Act of 2021. The original funds were accepted from three separate COVID-19 Supplements during the State of Emergency: \$576,526 was accepted on September 11, 2020; \$873,479 was accepted on October 30, 2020; and 576,526 was accepted on February 16, 2021. When the funding was originally accepted, the Notice of Award indicated that the funds were only good through 06/30/21. Since that time, the federal

funders have indicated that all COVID funds are good through 06/30/24. Because the end date of our initial request only went through 06/30/21, the funds were closed out in error at the end of the prior fiscal year.

The funds are to be budgeted as follows:

- Class 018 The funds will be used to pay for overtime of staff as required to carry out the duties.
- Class 030 The funds will be used to purchase cooling equipment for safe storage of vaccines.
- Class 038 The funds will be used to purchase software and licenses.
- Class 041 The funds will be used to pay for audit fund set aside.
- Class 050 The funds will be used to pay for part-time salaries of staff.
- Class 059 The funds will be used to continue to pay for the positions originally approved on September 11, 2020, positions: 9T3066, Program Specialist II; 9T3067, Program Specialist III; and 9T3068, Systems Development Specialist III.
- Class 060 The funds will be used to pay for benefits for the above positions.
- Class 070 The funds will be used to pay for in-state travel to perform required site visits of vaccine providers and in-person technical assistance.
- Class 102 The funds will be used to pay for contracts with the Regional Public Health Networks to expand infrastructure of community based organizations to increase capacity to promote COVID-19 vaccination.

The following information is provided in accordance with the comptroller's instructional memorandum dated September 21, 1981:

1. List of personnel involved: three positions will be continued utilizing this funding; as the positions were approved and filled after the initial accept and expend on September 11, 2020.
2. Nature, Need, and Duration: Continuation of these positions will support the COVID-19 response by increasing the state's capacity to implement effective immunization programs to prevent the occurrence of deadly infectious diseases, including COVID-19. These positions support critical immunization program functions related to ensuring: program oversight, quality assurance, communication with stakeholders, sub-recipient monitoring, compliance with Federal requirements and reporting, onboarding and technical assistance of information and data systems for COVID health care providers, increasing vaccination rates especially among populations disproportionately affected by COVID-19 and promoting campaigns to address vaccine hesitancy and promote vaccine confidence. The need for these positions to be continued is urgent, especially in light of COVID-19 response team demobilization. Two of three positions are currently filled. The duration for these positions will be 36 months.
3. Relationship to existing agency programs: This is an ongoing public health event and the CDC has continued support of the activities.
4. Has a similar program been requested of the legislature and denied? No.
5. Why wasn't funding included in the agency's budget request? At the time of budget submission, it was not known that this funding would be available.
6. Can portions of the grant funds be utilized? All grant dollars are being used for this request.
7. Estimate the funds required to continue these positions:

Positions (Salary & Benefits)	<u>FY 2022</u>	<u>FY2023</u>
Program Specialist II	\$ 76,803	\$ 80,449
Program Specialist III	\$ 22,813	\$ 88,784
Systems Development Specialist III	\$ 99,320	\$ 103,967

In response to the anticipated two-part question, "Can these funds be used to offset General Funds?" and "What is the compelling reason for not offsetting General Funds?" the Division offers the following information: The

funds are provided for a specified purpose by the CDC as defined in the Notice of Grant Award and cannot be used to offset general funds. These funds will not change the program eligibility levels. No new program will be established with the reacceptance of these funds.

Area served: Statewide

Source of Funds: 100% Federal Funds from the Centers for Disease Control and Prevention (CDC). The notice of three supplemental funds awarded were received June 4, 2020, September 23, 2020 and December 16, 2020. These funds were originally approved during New Hampshire's State of Emergency. They were granted to the State to assist in the public health Coronavirus response.

If Federal Funds become no longer available, General Funds will not be requested to support the program expenditures.

Respectfully submitted,



Lori A. Shibinette
Commissioner

1. DATE ISSUED *MM/DD/YYYY*
06/04/2020

1a. SUPERSEDES AWARD NOTICE dated 09/12/2019
except that any additions or restrictions previously imposed
remain in effect unless specifically rescinded

2. CFDA NO.
93.268 - Immunization Cooperative Agreements

3. ASSISTANCE TYPE Cooperative Agreement

4. GRANT NO. 6NH231P922595-01-02
Formerly

5. TYPE OF AWARD
Demonstration

4a. FA IN NH231P922595

5a. ACTION TYPE Post Award Amendment

6. PROJECT PERIOD *MM/DD/YYYY*
From 07/01/2019 Through 06/30/2024

7. BUDGET PERIOD *MM/DD/YYYY*
From 07/01/2019 Through 06/30/2020

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention

2939 Brandywine Road
Atlanta, GA 30341

NOTICE OF AWARD

AUTHORIZATION (Legislation/Regulations)
Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C.
Sections 247b, 247b(k)(2) and 247c), as amended.

8. TITLE OF PROJECT (OR PROGRAM)
CDC-RFA-IP19-1901 Immunization and Vaccines for Children

9a. GRANTEE NAME AND ADDRESS
HEALTH AND HUMAN SERVICES, NEW HAMPSHIRE DEPT OF
129 PLEASANT ST
CONCORD, NH 03301-3852

9b. GRANTEE PROJECT DIRECTOR
Ms. Colleen M. Haggerty
29 Hazen Dr.
CONCORD, NH 03301-6504
Phone: 603-271-4482

10a. GRANTEE AUTHORIZING OFFICIAL
Ms. Lisa M. Morris
29 Hazen Drive
Concord, NH 03301-6503
Phone: 603-271-4110

10b. FEDERAL PROJECT OFFICER
Gayle Daniels
1800 Clifton Rd
Atlanta, GA 30333
Phone: 404-639-6357

ALL AMOUNTS ARE SHOWN IN USD

11. APPROVED BUDGET (Excludes Direct Assistance)

I Financial Assistance from the Federal Awarding Agency Only

II Total project costs including grant funds and all other financial participation

a. Salaries and Wages	936,775.00
b. Fringe Benefits	443,850.00
c. Total Personnel Costs	1,380,625.00
d. Equipment	0.00
e. Supplies	21,320.00
f. Travel	43,918.00
g. Construction	0.00
h. Other	600,384.00
i. Contractual	1,973,000.00
j. TOTAL DIRECT COSTS	4,019,247.00
k. INDIRECT COSTS	349,069.00
l. TOTAL APPROVED BUDGET	4,368,316.00
m. Federal Share	4,368,316.00
n. Non-Federal Share	0.00

12. AWARD COMPUTATION

a. Amount of Federal Financial Assistance (from item 11m)	4,368,316.00
b. Less Unobligated Balance From Prior Budget Periods	0.00
c. Less Cumulative Prior Award(s) This Budget Period	3,791,790.00
d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION	576,526.00
13. Total Federal Funds Awarded to Date for Project Period	4,368,316.00

14. RECOMMENDED FUTURE SUPPORT
(Subject to the availability of funds and satisfactory progress of the project):

YEAR	TOTAL DIRECT COSTS	YEAR	TOTAL DIRECT COSTS
a. 2		d. 5	
b. 3		e. 6	
c. 4		f. 7	

15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:

a. DEDUCTION
b. ADDITIONAL COSTS
c. MATCHING
d. OTHER RESEARCH (Add / Deduct Option)
e. OTHER (See REMARKS)

b

16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:

a. The grant program legislation
b. The grant program regulations
c. This award notice including terms and conditions, if any, noted below under REMARKS.
d. Federal administrative requirements, cost principles and audit requirements applicable to this grant.

In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system.

REMARKS (Other Terms and Conditions Attached - Yes No)

GRANTS MANAGEMENT OFFICIAL:
Browlie Anderson-Rana, Grants Management Officer
2939 Flowers Road
Mallstop TY2
Atlanta, GA 30341-5509
Phone: 770-488-2771

17. OBJ CLASS	41.51	18a. VENDOR CODE	1026000618B5	18b. EIN	026000618	19. DUNS	011040545	20. CONG. DIST.	02
FY-ACCOUNT NO.		DOCUMENT NO.		ADMINISTRATIVE CODE		AMT ACTION FIN ASST		APPROPRIATION	
21. a.	0-9390EWQ	b.	19NH231P922595C3	c.	IP	d.	\$576,526.00	e.	75-2024-0943
22. a.		b.		c.		d.		e.	
23. a.		b.		c.		d.		e.	

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 3	DATE ISSUED 06/04/2020
GRANT NO. 6 NH23IP922595-01-02	

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

NOTICE OF AWARD (Continuation Sheet)

PAGE 3 of 3	DATE ISSUED 06/04/2020
GRANT NO. 6 NH23IP922595-01-02	

Federal Financial Report Cycle			
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date
07/01/2019	06/30/2020	Annual	09/28/2020

Project Abstract Summary

1. New Hampshire Immunization Program Immunizations and Vaccine for Children 2019-2023 Grant Application CDC-RFA-IP10-1901 The New Hampshire Immunization Program (NHIP) supports health systems with our shared goal of sustaining and increasing vaccine coverage rates across the lifespan, low incidence of vaccine-preventable diseases and the ability to respond to vaccine-preventable disease outbreaks. Our commitment to these goals is demonstrated through a strong foundation of staff in the core areas of Vaccine Accountability, Provider Quality Assurance, Immunization Information Systems, Epidemiology and Surveillance and through collaborative partnerships throughout the state. NH's universal vaccine purchase status prevents barriers to receipt of vaccine for all children birth through 18 years. This is accomplished through a combination of funding that highlights the commitment of many, including the NH Department of Health and Human Services (DHHS), the NH state legislature, the NH Department of Insurance, insurers and the federal Vaccine for Children (VFC) program. This combination of funding allows increased access to vaccine for all children by supplying all routinely recommended vaccines to enrolled health care providers. Section 317 funding of the Public Health Service Act authorizes awards to States, political subdivisions of States and to other public entities to assist in meeting the costs of health prevention services. NH priorities for Section 317 funding includes supporting public health infrastructure, maintaining an adequate supply of vaccine for uninsured adults and emergent vaccine needs. 317 funding is also prioritized for rapid response efforts related to vaccine-preventable disease outbreaks, including rapid VPD identification and investigation of cases/outbreaks, surveillance activities, laboratory testing, implementing vaccination and additional measures to control the spread of VPDs and future outbreaks. This financial opportunity will be directed towards achieving the work plan goals and objectives, based on the current Immunization Program Operations Manual (IPOM) and the mission of Healthy People 2030 that seeks "To promote, strengthen and evaluate the Nation's efforts to improve the health and well-being of all people". These goals and objectives include project activities focused on health care provider and public education and outreach, vaccine accountability, supporting immunization outreach, IIS procurement, implementation, maintenance and enhancement, and VPD surveillance. The current funding opportunity builds upon the previous foundation of work of the Immunization and VFC cooperative agreement which focused on supporting infrastructure and capacity to assure high vaccination coverage, low incidence of vaccine-preventable disease, maintaining and improving vaccine-preventable disease public health threats, and in recent years, the development of immunization systems to further advance immunization program work, the VFC cooperative agreement and other related immunization program initiatives and projects. The NH Immunization Program looks forward to our continued partnership with the Centers for Disease Control and Prevention and with our stakeholders throughout NH, protecting, promoting and improving the health and well-being of all NH citizens.

AWARD ATTACHMENTS

New Hampshire Dept of Health and Human Services

6 NH23IP922595-01-02

1. CARES Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number IP19- 1901, entitled Immunization and Vaccines for Children, which is hereby made a part of this Non- research award, hereinafter referred to as the Notice of Award (NoA).

Supplemental Funding: Additional funding in the amount \$576,526 is approved for the Year 01 budget period, which is July 1, 2019 through June 30, 2020

COVID-19: P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act) Activities

Recipients have **13 months** from the date of this NoA to expend all funds awarded herein

Budget/Workplan Revision Requirement: Within 30 days of this NoA, the recipient must submit a revised budget with a narrative justification outlining response activities. Failure to submit the required information in a timely manner may adversely affect the future funding of the project. If the information cannot be provided by the due date, you are required to contact your Project Officer and Grant Management Specialist. The revised budget must be uploaded in GrantSolutions as an amendment to allow issuance of a revised NoA.

Pre-Award Costs: Pre-award costs dating back to January 20, 2020 – when CDC first activated its Emergency Operations Center (EOC) – and directly related to the COVID-19 outbreak response are allowable.

Indirect Costs: Indirect cost will be approved based on current approved negotiated indirect cost rate agreement.

Overtime: Because overtime costs are a very likely and reasonable expense during the response to COVID-19, CDC will allow recipients to include projected overtime in their budgets. Recipients should be careful to estimate costs based on current real-time needs and will still be required to follow federal rules and regulations in accounting for the employees' time and effort.

Additional Term and Condition:

A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); and/or the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect

SARS-CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

Unallowable Costs:

- Research
- Clinical care
- Publicity and propaganda (lobbying):
 - Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:
https://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
- ***All unallowable costs cited in CDC-RFA-IP19-1901 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.***

REPORTING REQUIREMENTS

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Freda Johnson, Grants Management

Specialist Office of Grants Services (OGS)
Office of Financial Resources (OFR)
Office of the Chief Operating Officer (OCOO)
Centers for Disease Control and Prevention
(CDC) Wve2@cdc.gov | 404-488-3107 office

AND

U.S. Department of Health and Human Services Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator 330 Independence Avenue,
SW Cohen Building, Room 5527 Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or
Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1- 800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
CDC Office of Financial Resources

2939 Brandywine Road
 Atlanta, GA 30341

NOTICE OF AWARD

AUTHORIZATION (Legislation/Regulations)
 Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C.
 Sections 247b, 247b(k)(2) and 247c) as amended.

1. DATE ISSUED MM/DD/YYYY 09/23/2020		1a. SUPERSEDES AWARD NOTICE dated 06/21/2020 except that any additions or restrictions previously imposed remain in effect unless specifically rescinded	
2. CFDA NO. 93.288 - Immunization Cooperative Agreements			
3. ASSISTANCE TYPE Cooperative Agreement			
4. GRANT NO. 6 NH23IP922595-02-01 Formerly		5. TYPE OF AWARD Demonstration	
4a. FAIN NH23IP922595		5a. ACTION TYPE Post Award Amendment	
6. PROJECT PERIOD MM/DD/YYYY From 07/01/2019		Through 06/30/2024	
7. BUDGET PERIOD MM/DD/YYYY From 07/01/2020		Through 06/30/2021	
8. TITLE OF PROJECT (OR PROGRAM) CDC-RFA-IP19-1901 Immunization and Vaccines for Children			

9a. GRANTEE NAME AND ADDRESS
 HEALTH AND HUMAN SERVICES, NEW HAMPSHIRE DEPT OF
 129 PLEASANT ST
 CONCORD, NH 03301-3852

9b. GRANTEE PROJECT DIRECTOR
 Ms. Colleen M. Haggerty
 29 Hazen Dr.
 CONCORD, NH 03301-6504
 Phone: 603-271-4482

10a. GRANTEE AUTHORIZING OFFICIAL
 Ms. Lisa M. Morris
 29 Hazen Drive
 Concord, NH 03301-6503
 Phone: 603-271-4110

10b. FEDERAL PROJECT OFFICER
 Gayle Daniels
 1800 Clifton Rd
 Atlanta, GA 30333
 Phone: 404-639-6357

ALL AMOUNTS ARE SHOWN IN USD

11. APPROVED BUDGET (Excludes Direct Assistance)	
I Financial Assistance from the Federal Awarding Agency Only	
II Total project costs including grant funds and all other financial participation <input type="checkbox"/>	
a. Salaries and Wages	1,016,450.00
b. Fringe Benefits	489,744.00
c. Total Personnel Costs	1,506,194.00
d. Equipment	167,536.00
e. Supplies	239,832.00
f. Travel	26,267.00
g. Construction	0.00
h. Other	43,203.00
i. Contractual	1,814,565.00
j. TOTAL DIRECT COSTS	3,797,397.00
k. INDIRECT COSTS	351,162.00
l. TOTAL APPROVED BUDGET	4,148,559.00
m. Federal Share	4,148,559.00
n. Non-Federal Share	0.00

12. AWARD COMPUTATION	
a. Amount of Federal Financial Assistance (from Item 11m)	4,148,559.00
b. Less Unobligated Balance From Prior Budget Periods	950,000.00
c. Less Cumulative Prior Award(s) This Budget Period	2,319,549.00
d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION	879,010.00
13. Total Federal Funds Awarded to Date for Project Period	7,568,875.00

14. RECOMMENDED FUTURE SUPPORT (Subject to the availability of funds and satisfactory progress of the project):			
YEAR	TOTAL DIRECT COSTS	YEAR	TOTAL DIRECT COSTS
a. 3		d. 6	
b. 4		e. 7	
c. 5		f. 8	

15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:

a. DEDUCTION	<input type="checkbox"/>
b. ADDITIONAL COSTS	
c. MATCHING	
d. OTHER RESEARCH (Add / Deduct Option)	
e. OTHER (See REMARKS)	

16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARDING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:

a. The grant program legislation
b. The grant program regulations
c. This award notice including terms and conditions, if any, noted below under REMARKS.
d. Federal administrative requirements, cost principles and audit requirements applicable to this grant.

In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system.

REMARKS (Other Terms and Conditions Attached - Yes No)
 ACTION ITEM - Respond to the comments shown in the Grant Notes titled "OGS Budget Review Comments" and the technical review from Program within 30 days of the issue date shown on this Notice of Award. Please upload the response as a Grant Note.

GRANTS MANAGEMENT OFFICIAL:
 Brownie Anderson-Rena, Grants Management Officer
 2839 Flowers Road
 Mallstop TV2
 Atlanta, GA 30341-5509
 Phone: 770-488-2771

17. OBJ CLASS	41.51	18a. VENDOR CODE	1026000618B5	18b. EIN	026000618	19. DUNS	011040545	20. CONG. DIST.	02
FY-ACCOUNT NO.		DOCUMENT NO.		ADMINISTRATIVE CODE		AMT ACTION FIN ASST		APPROPRIATION	
21. a.	0-9390BKG	b.	19NH23IP922595	c.	IP	d.	\$55,301.00	e.	75-75-X-0512-009
22. a.	0-9390FG3	b.	20NH23IP922595C3	c.	IP	d.	\$823,709.00	e.	75-2024-0943
23. a.		b.		c.		d.		e.	

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 3	DATE ISSUED 09/23/2020
GRANT NO. 6 NH23IP922595-02-01	

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

NOTICE OF AWARD (Continuation Sheet)

PAGE 3 of 3	DATE ISSUED 09/23/2020
GRANT NO. 6 NH23IP922595-02-01	

Federal Financial Report Cycle			
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date
07/01/2019	06/30/2020	Annual	09/28/2020
07/01/2020	06/30/2021	Annual	09/28/2021

AWARD ATTACHMENTS

New Hampshire Dept of Health and Human Services

6 NH23IP922595-02-01

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number IP19-1901, entitled, *Immunization and Vaccines for Children*, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Supplemental Component Funding: Additional funding in the amount \$879,010 is approved for the Year 02 budget period, which is July1, 2020 through June 30, 2021.

The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

NOFO Component	Amount
Core Funding	\$55,301
COVID-19 - CARES	\$823,709

Recipients have until July 5, 2021 to expend all COVID-19 funds awarded herein

Overtime: Because overtime costs are a very likely and reasonable expense during the response to COVID-19, CDC will allow recipients to include projected overtime in their budgets. Recipients should be careful to estimate costs based on current real-time needs and will still be required to follow federal rules and regulations in accounting for the employees' time and effort.

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); and/or the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting guidance is posted at: <https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf>.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the

purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

Unallowable Costs:

- Research
- Clinical care
- Publicity and propaganda (lobbying):
 - Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:
https://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
- All unallowable costs cited in CDC-RFA-CK19-1904 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

COVID-19 and VFC Funding Budget Revision Requirement: The recipient must submit a revised budget with a narrative justification and/or workplan within 30 days after the receipt of this Notice of Award. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date. **A separate narrative and workplan must be submitted in accordance with the COVID-19 guidance and must also be uploaded in GMM as an amendment with a SF424A.**

REPORTING REQUIREMENTS

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information

related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Freda Johnson, Grants Management Specialist
Centers for Disease Control and Prevention
Branch 1
2939 Flowers Road, MS-TV-2
Atlanta, GA 30341
Email: FJohnson@5@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures;
Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201
Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line)
or Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION:

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Component: CORE

Document Number: 19NH23IP922595

Component: COVID-19

Document Number: 20NH23IP922595C3

GDC Staff/Contacts

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

GMS Contact Information:

Freda Johnson, Grants Management Specialist
Centers for Disease Control and Prevention
Branch 1
2939 Flowers Road, MS TV2
Atlanta, GA 30341
Phone: 770-488-3107
E-mail: Fjohnson5@cdc.gov



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award

Award# 6 NH23IP922595-02-02

FAIN# NH23IP922595

Federal Award Date: 12/16/2020

Recipient Information

1. Recipient Name
New Hampshire Dept of Health and Human Services
129 PLEASANT ST
CONCORD, NH 03301-3852
[NO DATA]

2. Congressional District of Recipient
02

3. Payment System Identifier (ID)
1026000618B5

4. Employer Identification Number (EIN)
026000618

5. Data Universal Numbering System (DUNS)
011040545

6. Recipient's Unique Entity Identifier

7. Project Director or Principal Investigator

Ms. Colleen M. Haggerty
Colleen.Haggerty@dhs.nh.gov
603-271-4482

8. Authorized Official

Ms. Lisa M. Morris
Director
lisa.morris@dhs.nh.gov
603-271-4110

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Freda Johnson
wvc2@cdc.gov
770.488.3107

10. Program Official Contact Information

Gayle Daniels
gz54@cdc.gov
404-639-6357

Federal Award Information

11. Award Number

6 NH23IP922595-02-02

12. Unique Federal Award Identification Number (FAIN)

NH23IP922595

13. Statutory Authority

Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C. Sections 247b, 247b(k)(2) and 247c), as

14. Federal Award Project Title

CDC-RFA-IP19-1901 Immunization and Vaccines for Children

15. Assistance Listing Number

93.268

16. Assistance Listing Program Title

Immunization Cooperative Agreements

17. Award Action Type

Supplement

18. Is the Award R&D?

No

Summary Federal Award Financial Information

Table with 2 columns: Item Number and Amount. Includes rows for Budget Period Start Date, Total Amount of Federal Funds Obligated, Authorized Carryover, and Total Federal and Non-Federal Approved.

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Brownie Anderson-Rana
Grants Management Officer

30. Remarks



Recipient Information	
Recipient Name New Hampshire, Dept of Health and Human Services 129 PLEASANT ST CONCORD, NH 03301-3852 [NO DATA]	
Congressional District of Recipient 02	
Payment Account Number and Type 1026000618B5	
Employer Identification Number (EIN) Data 026000618	
Universal Numbering System (DUNS) 011040545	
Recipient's Unique Entity Identifier Not Available	
31. Assistance Type Cooperative Agreement	
32. Type of Award Demonstration	

33. Approved Budget (Excludes Direct Assistance)	
i. Financial Assistance from the Federal Awarding Agency Only	
ii. Total project costs including grant funds and all other financial participation	
a. Salaries and Wages	\$1,116,450.00
b. Fringe Benefits	\$509,324.00
c. Total Personnel Costs	\$1,625,774.00
d. Equipment	\$167,536.00
e. Supplies	\$239,632.00
f. Travel	\$26,267.00
g. Construction	\$0.00
h. Other	\$71,234.00
i. Contractual	\$2,243,480.00
j. TOTAL DIRECT COSTS	\$4,373,923.00
k. INDIRECT COSTS	\$351,162.00
l. TOTAL APPROVED BUDGET	\$4,725,085.00
m. Federal Share	\$4,725,085.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes					
FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-9390FG3	20NH23IP922595C3	IP	41.51	\$576,526.00	75-2024-0943



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH23IP922595-02-02

FAIN# NH23IP922595

Federal Award Date: 12/16/2020

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH23IP922595-02-02

FAIN# NH23IP922595

Federal Award Date: 12/16/2020

35. Terms And Conditions

Federal Financial Report Cycle			
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date
07/01/2019	06/30/2020	Annual	09/28/2020
07/01/2020	06/30/2021	Annual	09/28/2021

AWARD ATTACHMENTS

New Hampshire Dept of Health and Human Services

6 NH23IP922595-02-02

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number IP19-1901, entitled, *Immunization and Vaccines for Children*, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Supplemental Component Funding: Additional funding in the amount \$576,526 is approved for the Year 02 budget period, which is July 1, 2020 through June 30, 2021.

The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

NOFO Component	Amount
COVID-19	\$576,526

Recipients have until June 30, 2022 to expend all COVID-19 funds awarded in Year 2

Overtime: Because overtime costs are a very likely and reasonable expense during the response to COVID-19, CDC will allow recipients to include projected overtime in their budgets. Recipients should be careful to estimate costs based on current real-time needs and will still be required to follow federal rules and regulations in accounting for the employees' time and effort.

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); and/or the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting guidance is posted at: <https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf>.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the

purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

Unallowable Costs:

- Research
- Clinical care
- Publicity and propaganda (lobbying):
 - Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:
https://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
- All unallowable costs cited in CDC-RFA-IP19-1901 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

ADMINISTRATIVE REQUIREMENTS

The recipient must respond to the comments in the technical review and/or OGS Budget Comments in accordance with the recommendations provided in GrantSolutions as a Grant Note within 45 days of receipt of the Notice of Award. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the Awarding Agency Contact Information section on the first page before the due date.

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIS):

Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Freda Johnson, Grants Management Specialist
Centers for Disease Control and Prevention
Branch 1
2939 Flowers Road, MS-TV-2
Atlanta, GA 30341
Email: kcr8@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures,
Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201
Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line)
or Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.